Advertise | About Us | Contact Us

Article - Issue 63

Beyond Human Intuition

Article - Issue 63

Reinvent Drug Development and Safety with AI

Article - Issue 63

Reimagining Pharmacovigilance

Article - Issue 63

Rethinking Inflammation

Article - Issue 63

Beyond Trial and Error

EDITORIAL SECTIONS

Why X-ray Inspection is a Viable Quality Assurance Solution for Pharma Products

Adopting the Power of AI to Drug Development Projects

A tremendous amount of documentation is created throughout the clinical trial lifecycle

Real-world Evidence

Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA

Just in Time Manufacturing Creating more sustainable supply chains

Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine

Challenges and Advantages of Using Artificial Intelligence in Pharma

Many advanced largescale AI initiatives still need to be proved successful in Pharma

Advisory Board

Victor M. Diaz Perez

Brian D Smith

Nigel Cryer FRSC

Quang Bui

Tamara Miller

Imedla Leslie Rillon

Andri Kusandri

Nicoleta Grecu

Alessio Piccoli

Pramod Kashid

Neil J Campbell

Rise of Enabling Technologies in Pharmaceutical Formulation Development and Manufacturing

Director, Formulation Development, Exelixis, Inc
Kasturi Pawar is a leading pharmaceutical scientist with a PhD in pharmaceutical sciences She has significantly contributed to the field of pharmaceutics Her research and experience have been focused on formulation development drug delivery and clinical supply chain Currently working as a Director in Formulation Development at Exelixis Inc she holds several publications and patents on drug deliver...

Articles

The Therapeutics Landscape of Miniproteins

marks years since the approval of the first monoclonal antibody mAb muromononabCD OKT in Over four decades the pharmaceutical industry has accumulated an extraordinary body of knowledge on how to discover engineer manufacture and safely administer antibodybased therapeutics

Research Insights

Changing Paradigms In Bioequivalence Trials Submitted To The Ema For Evaluation – A Clinical And Regulatory Perspective

Abstract Background The selection of a robust bioequivalence BE study designs for registering a generic product remains still a hard task This task is still challenging despite the fact that generic products are much needed by health care providers in economical terms Thus BE study designs could be a means to

Case Studies

Solid Form Changes During Drug Development: Good, Bad, And Ugly Case Studies

The relevance of solid form in drug development has been well established over time In order to fully understand drug properties attention has been paid to solid state structure of drug molecules and their relationship to the drug formulation While each drug developer has had their own strategies and workflows for screening and choosing solid forms of drug molecules t...

Techno Trends

Duke-NUS Medical School Discovered Breakthrough Treatment for Neurodevelopmental Disorders

Researchers at DukeNUS Medical School and the Mechanobiology Institute MBI at the National University of Singapore NUS have uncovered a novel pathway that can awaken dormant neural stem cells paving the way for potential new therapies for neurodevelopmental disorders such

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

Government Investment in AI Capabilities will Cement Singapore’s Position as a Premier Clinical Trial Location

Edwin Ng

Edwin Ng joined Medidata in 2014 and heads the Life Science industry of Dassault Systemes across the Asia Pacific region. Under his leadership, the company’s regional business recorded significant year-on-year growth and achieved multiple leadership awards. Edwin has spent the last 27 years of his career managing enterprise solutions businesses.

Marine Biomaterials for Drug Delivery Applications

Innocent J Macha

Macha has six years of experience in research and teaching in the area of biomaterials synthesis and characterisations, drug delivery devices, cell culture and bacterial biofilm. He is also Associate Editor of the Journal of The Australian Ceramic Society and has published more than 14 articles and 6 book chapters.

Reshaping the Clinical Trial Model

Anna Hayes

Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.

Perspectives on the Vaccine Industry

Josephine Cheng

As a Senior Consultant in Bioprocessing Strategy at Merck with over 14 years of
international biopharma experience, Josephine Cheng focuses on vaccine and mRNA market segments, where she translates strategies into market initiatives to enable the utilisation of best-in-class technologies and transforms industry insights into sustainable business strategies.
Josephine obtained Bachelor's and Master's degrees in Bio-resource's; Agriculture from the National Taiwan University.

Natural Polymers and Fibers in Drug Delivery

Dr. Meghraj V. Suryawanshi

Dr. Meghraj V. Suryawanshi is an Associate Professor and Co-Founder of Sandip Institute of Pharmaceutical Sciences. He holds M.Pharm, MBA, PDCR, and Ph.D. degrees. With over 7 years of research experience and 4 years in teaching, his expertise lies in polymer science, novel drug delivery systems (NDDS), and intellectual property rights (IPR). Dr. Suryawanshi has authored more than 55 publications, 8 books, and holds several patents. He actively leads innovative pharmaceutical research with a strong focus on translational impact.

Akshata Yashwant Patne

Akshata Yashwant Patne is a pharmaceutical nanotechnology expert with over 3 years of experience in clinical research, drug delivery, and AI-driven therapeutics. She has led nanoparticle-based studies, published peer-reviewed articles, and actively mentors students, combining science, innovation, and leadership across academia, research, and global scientific communities.

INDUSTRY UPDATES

press releasesRead more...

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix Pharmaceuticals Limited ASX TLX NASDAQ TLX Telix today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE ITM a global leader

BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

Boomray Pharmaceuticals Co Ltd BoomRay a clinicalstage biotechnology company pioneering innovative radioligand therapies RLTs for precision oncology diagnostics and therapeutics

Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NewAmsterdam Pharma Company NV Nasdaq NAMS or NewAmsterdam or the Company a latestage clinical biopharmaceutical company developing oral nonstatin medicines for patients at risk

University of Sydney launches Australia's new ace against cancer

An Australianfirst cancer research facility that will allow scientists to examine individual cancer and immune cells in unprecedented detail has officially opened at the University of Sydney marking

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

Tempus AI Inc NASDAQ TEM today announced an extension of its data license agreement with Recursion Pharmaceuticals Inc NASDAQ RXRX Additionally the two companies have entered

WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion

WuXi XDC Cayman Inc a leading global Contract Research Development and Manufacturing Organization CRDMO focused on the bioconjugate industry today held a grand GMP release ceremony